RESUMEN
Organophosphate intoxication via acetylcholinesterase inhibition executes neurotoxicity via hyper stimulation of acetylcholine receptors. Here, we use the organophosphate paraoxon-ethyl to treat C. elegans and use its impact on pharyngeal pumping as a bio-assay to model poisoning through these neurotoxins. This assay provides a tractable measure of acetylcholine receptor mediated contraction of body wall muscle. Investigation of the time dependence of organophosphate treatment and the genetic determinants of the drug-induced inhibition of pumping highlight mitigating modulation of the effects of paraoxon-ethyl. We identified mutants that reduce acetylcholine receptor function protect against the consequence of intoxication by organophosphates. Data suggests that reorganization of cholinergic signalling is associated with organophosphate poisoning. This reinforces the under investigated potential of using therapeutic approaches which target a modulation of nicotinic acetylcholine receptor function to treat the poisoning effects of this important class of neurotoxins.
Asunto(s)
Intoxicación por Organofosfatos , Receptores Nicotínicos , Animales , Intoxicación por Organofosfatos/tratamiento farmacológico , Paraoxon/uso terapéutico , Paraoxon/toxicidad , Inhibidores de la Colinesterasa/uso terapéutico , Caenorhabditis elegans/genética , Caenorhabditis elegans/metabolismo , Acetilcolinesterasa/metabolismo , Receptores Nicotínicos/genética , Neurotoxinas , Organofosfatos/toxicidad , Organofosfatos/uso terapéuticoRESUMEN
SUMMARY: The cholinergic nervous system has been demonstrated to attenuate the inflammatory response during sepsis via the inhibitory action of acetylcholine (ACh) on macrophages. These findings were largely based on experimental sepsis models using endotoxin as the inducing agent. Herein, however, we report that the specific inhibition of acetylcholinesterase (AChE) renders animals more resistant to infection by a virulent strain of Salmonella enterica serovar Typhimurium, a Gram-negative enteric pathogen. Inhibition of AChE was induced by a subchronic exposure to paraoxon, a potent anti-cholinesterase metabolite of the organophosphorous compound parathion. Our findings indicate that inhibition of AChE enhanced survival of infected mice in a dose-dependent fashion and this correlated with efficient control of bacterial proliferation in target organs. Immunologically, inhibition of AChE enabled the animals to mount a more effective inflammatory anti-microbial response, and to secrete higher levels of interleukin-12, a key T helper type 1-promoting cytokine. The ACh-induced enhancement in resistance to infection was abrogated by co-administration of an oxime which can reactivate AChE. Hence, in a model of Gram-negative bacterial infection, cholinergic stimulation is shown to enhance the anti-microbial immune response leading to effective control of bacterial proliferation and enhanced animal survival.
Asunto(s)
Inhibidores de la Colinesterasa/farmacología , Sistema Inmunológico/efectos de los fármacos , Infecciones por Salmonella/microbiología , Infecciones por Salmonella/prevención & control , Salmonella typhimurium , Acetilcolinesterasa/metabolismo , Animales , Linfocitos B/citología , Recuento de Células , Inhibidores de la Colinesterasa/uso terapéutico , Reactivadores de la Colinesterasa/farmacología , Concanavalina A/farmacología , Citocinas/sangre , Citocinas/metabolismo , Eritrocitos/efectos de los fármacos , Eritrocitos/metabolismo , Proteínas Ligadas a GPI , Sistema Inmunológico/inmunología , Lipopolisacáridos/farmacología , Ganglios Linfáticos/microbiología , Macrófagos/citología , Macrófagos/efectos de los fármacos , Macrófagos/metabolismo , Masculino , Ratones , Ratones Endogámicos BALB C , Óxido Nítrico/metabolismo , Oximas/farmacología , Paraoxon/farmacología , Paraoxon/uso terapéutico , Compuestos de Piridinio/farmacología , Infecciones por Salmonella/sangre , Infecciones por Salmonella/tratamiento farmacológico , Salmonella typhimurium/patogenicidad , Bazo/citología , Bazo/efectos de los fármacos , Bazo/microbiología , Análisis de Supervivencia , Linfocitos T/citología , Linfocitos T/efectos de los fármacos , Linfocitos T/metabolismo , Timo/efectos de los fármacosRESUMEN
Type I diabetes (T1D) is a T cell-driven autoimmune disease that results in the killing of pancreatic ß-cells and, consequently, loss of insulin production. Using the multiple low-dose streptozotocin (MLD-STZ) model of experimental autoimmune diabetes, we previously reported that pretreatment with a specific acetylcholinesterase inhibitor (AChEI), paraoxon, prevented the development of hyperglycemia in C57BL/6 mice. This correlated with an inhibition of T cell infiltration into the pancreatic islets and a reduction in pro-inflammatory cytokines. The cholinergic anti-inflammatory pathway utilizes nicotinic and muscarinic acetylcholine receptors (nAChRs and mAChRs, respectively) expressed on a variety of cell types. In this study, we carried out a comparative analysis of the effect of specific antagonists of nAChRs or mAChRs on the development of autoimmune diabetes. Co-administration of mecamylamine, a non-selective antagonist of nAChRs maintained the protective effect of AChEI on the development of hyperglycemia. In contrast, co-administration of atropine, a non-selective antagonist of mAChRs, mitigated AChEI-mediated protection. Mice pretreated with mecamylamine had an improved response in glucose tolerance test (GTT) than mice pretreated with atropine. These differential effects of nAChR and mAChR antagonists correlated with the extent of islet cell infiltration and with the structure and functionality of the ß-cells. Taken together, our data suggest that mAChRs are essential for the protective effect of cholinergic stimulation in autoimmune diabetes.
Asunto(s)
Diabetes Mellitus Experimental/metabolismo , Diabetes Mellitus Tipo 1/metabolismo , Receptores Muscarínicos/metabolismo , Receptores Nicotínicos/metabolismo , Acetilcolinesterasa/sangre , Animales , Atropina/farmacología , Diabetes Mellitus Experimental/inducido químicamente , Modelos Animales de Enfermedad , Femenino , Proteínas Ligadas a GPI/antagonistas & inhibidores , Proteínas Ligadas a GPI/sangre , Hiperglucemia/tratamiento farmacológico , Hiperglucemia/metabolismo , Células Secretoras de Insulina/metabolismo , Masculino , Mecamilamina/farmacología , Ratones , Ratones Endogámicos C57BL , Antagonistas Muscarínicos/farmacología , Antagonistas Nicotínicos/farmacología , Paraoxon/farmacología , Paraoxon/uso terapéutico , Estreptozocina/farmacologíaRESUMEN
Inflammation is a crucial defense mechanism that protects the body from the devastating effects of invading pathogens. However, an unrestrained inflammatory reaction may result in systemic manifestations with dire consequences to the host. The extent of activation of the inflammatory response is tightly regulated through immunological and neural pathways. Previously, we demonstrated that cholinergic stimulation confers enhanced protection in experimental animals orally infected with virulent Salmonella enterica serovar Typhimurium. In this study, we investigated the mechanism by which this enhanced protection takes place. Cholinergic stimulation was induced by a 3-week pretreatment with paraoxon, a highly specific acetylcholinesterase (AChE) inhibitor. This treatment enhanced host survival following oral-route infection and this correlated with significantly reduced bacterial load in systemic target organs. Enhanced protection was not due to increased gut motility or rapid bacterial clearance from the gastrointestinal tract. Moreover, protection against bacterial infection was not evident when the animals were infected systemically, suggesting that acetylcholine-mediated protective effect was mostly confined to the gut mucosal tissue. In vivo imaging demonstrated a more localized infection and delay in bacterial dissemination into systemic organs in mice pretreated with paraoxon. Morphological analysis of the small intestine (ileum) showed that AChE inhibition induced the degranulation of goblet cells and Paneth cells, two specialized secretory cells involved in innate immunity. Our findings demonstrate a crucial pathway between neural and immune systems that acts at the mucosal interface to protect the host against oral pathogens.
Asunto(s)
Agonistas Colinérgicos/uso terapéutico , Inhibidores de la Colinesterasa/uso terapéutico , Íleon/patología , Mucosa Intestinal/inmunología , Paraoxon/uso terapéutico , Salmonella typhi/fisiología , Fiebre Tifoidea/tratamiento farmacológico , Acetilcolinesterasa/metabolismo , Administración Oral , Animales , Carga Bacteriana/efectos de los fármacos , Degranulación de la Célula/efectos de los fármacos , Células Cultivadas , Citocinas/metabolismo , Modelos Animales de Enfermedad , Humanos , Inmunidad Innata/efectos de los fármacos , Mucosa Intestinal/patología , Masculino , Ratones , Ratones Endogámicos BALB C , NeuroinmunomodulaciónRESUMEN
The use of cholinesterase inhibitors in poisonings with potentially lethal doses of tricyclic antidepressive drugs seems to be indicated on account of clinical experiences and own experimental investigations on animals. An uncritical use of these substances which have considerable side-effects must be warned of. A mixed intoxication with several drugs effecting on the central nervous system is only a relative indication for the use of indirect parasympathicomimetics of the cholinesterase type. They should be used only then, when the picture of poisoning is unequivocally determined by the thymoleptics. When cholinesterase inhibitors are used the physostigmine salicylate should be preferred, since at present it is sufficiently accessible to the central nervous system and with the slightest peripheral effects as the only representative of this group of substances, above all with regard to the gastrointestinal motility. Later investigations shall show, whether also other groups of substances which develop an antagonistic effect to the tricyclic antidepressive drugs may be of use in the treatment of the acute poisoning.